China NT Pharma Group Company Limited
HKEX:1011.HK
0.365 (HKD) • At close May 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 37.96 | 7.366 | 207.092 | 226.699 | 221.731 | 365.969 | 571.521 | 604.846 | 915.119 | 847.726 | 864.621 | 754.115 | 739.132 | 2,758.142 | 2,667.978 |
| Cost of Revenue
| 32.7 | 0 | 81.806 | 81.24 | 86.827 | 105.086 | 149.519 | 120.611 | 421.49 | 396.219 | 473.28 | 465.147 | 467.313 | 1,867.496 | 2,004.775 |
| Gross Profit
| 5.26 | 7.366 | 125.286 | 145.459 | 134.904 | 260.883 | 422.002 | 484.235 | 493.629 | 451.507 | 391.341 | 288.968 | 271.819 | 890.646 | 663.203 |
| Gross Profit Ratio
| 0.139 | 1 | 0.605 | 0.642 | 0.608 | 0.713 | 0.738 | 0.801 | 0.539 | 0.533 | 0.453 | 0.383 | 0.368 | 0.323 | 0.249 |
| Reseach & Development Expenses
| 0 | 0 | 3.762 | 5.959 | 8.996 | 17.087 | 34.188 | 8.415 | 6.911 | 4.477 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 18.486 | 63.574 | 59.878 | 80.659 | 96.253 | 163.82 | 178.994 | 151.837 | 110.069 | 90.977 | 81.443 | 91.215 | 129.297 | 129.082 | 90.056 |
| Selling & Marketing Expenses
| 0 | 0 | 46.239 | 149.863 | 123.074 | 93.023 | 183.483 | 91.852 | 201.447 | 228.899 | 264.583 | 375.807 | 579.826 | 452.834 | 354.456 |
| SG&A
| 18.486 | 63.574 | 106.117 | 230.522 | 219.327 | 256.843 | 362.477 | 243.689 | 311.516 | 319.876 | 346.026 | 467.022 | 709.123 | 581.916 | 444.512 |
| Other Expenses
| 0 | 0 | 11.438 | -2.13 | -1.503 | -2.038 | -302.161 | 16.787 | 3.269 | -26.512 | 0.598 | 0.678 | 0.224 | -56.822 | -36.846 |
| Operating Expenses
| 18.486 | 63.574 | 117.555 | 228.392 | 217.824 | 254.805 | 361.485 | 229.251 | 308.785 | 293.364 | 342.516 | 464.408 | 706.997 | 525.094 | 407.666 |
| Operating Income
| -13.226 | -56.208 | 18.437 | -59.277 | -68.134 | -22.047 | -246.564 | 269.578 | 185.666 | 135.957 | 96.071 | -577.638 | -1,117.19 | 365.552 | 255.537 |
| Operating Income Ratio
| -0.348 | -7.631 | 0.089 | -0.261 | -0.307 | -0.06 | -0.431 | 0.446 | 0.203 | 0.16 | 0.111 | -0.766 | -1.511 | 0.133 | 0.096 |
| Total Other Income Expenses Net
| -40.254 | 22.839 | -23.498 | -89.475 | -117.369 | -148.981 | -315.435 | 1.347 | -29.032 | -35.252 | -78.744 | -75.203 | -60.098 | -58.083 | -45.379 |
| Income Before Tax
| -53.48 | -33.369 | -54.296 | -148.752 | -200.289 | -583.472 | -561.999 | 226.428 | 156.603 | 100.705 | 17.327 | -652.841 | -1,177.288 | 307.469 | 210.158 |
| Income Before Tax Ratio
| -1.409 | -4.53 | -0.262 | -0.656 | -0.903 | -1.594 | -0.983 | 0.374 | 0.171 | 0.119 | 0.02 | -0.866 | -1.593 | 0.111 | 0.079 |
| Income Tax Expense
| 0.123 | 0.122 | 12.109 | 2.582 | -9.02 | 9.73 | 39.86 | 15.883 | 40.843 | 13.011 | 15.24 | 20.617 | -67.972 | 73.092 | 80.748 |
| Net Income
| -53.357 | -143.59 | -66.405 | -151.334 | -191.269 | -593.202 | -957.666 | 165.195 | 116.181 | 87.694 | 2.087 | -673.458 | -1,109.316 | 234.377 | 128.61 |
| Net Income Ratio
| -1.406 | -19.494 | -0.321 | -0.668 | -0.863 | -1.621 | -1.676 | 0.273 | 0.127 | 0.103 | 0.002 | -0.893 | -1.501 | 0.085 | 0.048 |
| EPS
| -0.2 | -0.17 | -0.035 | -0.08 | -0.1 | -0.34 | -0.61 | 0.11 | 0.075 | 0.062 | 0.002 | -0.62 | -1.03 | 0.23 | 0.16 |
| EPS Diluted
| -0.2 | -0.73 | -0.035 | -0.08 | -0.1 | -0.34 | -0.61 | 0.091 | 0.075 | 0.061 | 0.002 | -0.62 | -1.03 | 0.23 | 0.16 |
| EBITDA
| -8.65 | 1.33 | 10.395 | -17.776 | -43.737 | -155.974 | -210.917 | 303.569 | 86.285 | 143.25 | 118.535 | -555.435 | -1,097.446 | 389.795 | 272.961 |
| EBITDA Ratio
| -0.228 | 0.181 | 0.05 | -0.078 | -0.197 | -0.426 | -0.369 | 0.502 | 0.094 | 0.169 | 0.137 | -0.737 | -1.485 | 0.141 | 0.102 |